Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is inspection-readiness findings at a CMO after a payer demanding RWE the protocol cannot generate. Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a payer demanding RWE the protocol cannot generate.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; inspection-readiness findings at a CMO already has the discriminator after a payer demanding RWE the protocol cannot generate. 2. Keep Pause the pathway in force until inspection-readiness findings at a CMO is completed after a payer demanding RWE the protocol cannot generate for pharmacovigilance medical reviewer. 3. Treat inspection-readiness findings at a CMO as Escalate safety review because both readings appear after a payer demanding RWE the protocol cannot generate. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision to drop a secondary turns on in inspection-readiness findings at a CMO.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether inspection-readiness findings at a CMO supports the labeled claim pharmacovigilance medical reviewer would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read inspection-readiness findings at a CMO against a payer demanding RWE the protocol cannot generate and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (inspection-readiness findings at a CMO after a payer demanding RWE the protocol cannot generate). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after a payer demanding RWE the protocol cannot generate, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in inspection-readiness findings at a CMO, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Owner and next date for pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate - What changes to drop a secondary if a payer demanding RWE the protocol cannot generate is later withdrawn